Actuate Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Actuate Therapeutics, Inc. (ACTU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 950.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 950.00K shares, a 2.16% increase year-over-year.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 37.50K shares, a 16.67% decline year-over-year.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 30.00K shares, a 91.89% decline year-over-year.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.08M shares, a 98.50% increase from fiscal 2024.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 542.75K shares, a 104.38% increase from fiscal 2023.
- Actuate Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 265.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 950.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 950.00K shares 10-Q · filed 2026-08-14 | 987.50K shares derived: sum of 3 quarters · filed 2026-08-14 | 1.02M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 37.50K shares derived: sum of 2 quarters · filed 2026-05-14 | 67.50K shares derived: sum of 3 quarters · filed 2026-05-14 | 997.38K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 37.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 67.50K shares derived: sum of 2 quarters · filed 2026-03-26 | 997.38K shares derived: sum of 3 quarters · filed 2026-03-26 | 1.08M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 959.88K shares derived: sum of 2 quarters · filed 2025-11-13 | 1.04M shares 10-Q · filed 2025-11-13 | 1.08M shares derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | 929.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 1.01M shares 10-Q · filed 2025-08-14 | 1.05M shares derived: sum of 3 quarters · filed 2026-03-26 | 1.42M shares derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | 80.00K shares 10-Q · filed 2025-05-15 | 125.00K shares derived: sum of 2 quarters · filed 2026-03-26 | 494.97K shares derived: sum of 3 quarters · filed 2026-03-26 | |
| 2024-12-31 | 45.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 414.97K shares derived: sum of 2 quarters · filed 2026-03-26 | 542.75K shares 10-K · filed 2026-03-26 | |
| 2024-09-30 | 369.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 497.75K shares 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 127.78K shares 10-Q · filed 2024-09-24 | |||
| 2023-12-31 | 265.57K shares 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |